Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Adipotide and Mazdutide — mechanism, side effects, legal status, and pricing.
Adipotide (FTPP) is a chimeric peptidomimetic developed in the Arap/Pasqualini lab (originally at MD Anderson) that couples a 9-residue homing motif (CKGGRAKDC) — isolated by in vivo phage display as a ligand for prohibitin on white-adipose-tissue vasculature — to the D-amino-acid pro-apoptotic domain D(KLAKLAK)2. It is an experimental research compound, NOT FDA-approved for any indication. A clinical-development program in prostate-cancer-associated obesity reached early-phase testing and was ultimately discontinued.
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Adipotide
Mazdutide
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Adipotide
Mazdutide
COA corpus from Disclosed Labs — independently tested batches only.
Adipotide
2
COAs
98.8%
Avg purity
2
Labs
Mazdutide
6
COAs
99.7%
Avg purity
4
Labs
Foundational proof-of-concept in obese mice (Kolonin et al., Nat Med 2004, PMID 15133506). A 4-week dosing study in spontaneously obese rhesus macaques showed substantial body-weight and fat-mass loss and improved insulin sensitivity but produced dose-dependent renal proximal-tubule toxicity (Barnhart et al., Sci Transl Med 2011, PMID 22072637). A small Phase 1 trial in obese prostate-cancer patients was initiated and later terminated; the program was permanently discontinued. No published human efficacy data. Grey-market human use is unstudied and carries documented nephrotoxicity risk.
Phase 3 GLORY-1 (Ji et al., NEJM 2025) in 610 Chinese adults with obesity/overweight reported mean weight loss of ~11.0% (4 mg) and ~14.0% (6 mg) vs +0.3% placebo at 48 weeks. Additional Phase 3 programs (GLORY-2 obesity, DREAMS-1/2/3 T2DM) supported the NMPA approvals; a 9 mg supplementary application for moderate-to-severe obesity is under NMPA review.
Adipotide and Mazdutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing
Disclosed Labs